Archive for November 5th, 2011

Pipeline updates for THLD DRRX BCRX CLDX AVEO VNDA ANTH ZIOP SCMP NKTR

Nov 05, 2011 No Comments by

Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) said that it hopes to report top line efficacy analysis results from the randomized Phase 2 trial in pancreatic cancer around the end of 2011, and provide an update on the interim analysis from the pivotal Phase 3 clinical trial of TH-302 plus doxorubicin compared to doxorubicin alone in patients […]

Daily News Read more

Pipeline updates for XNPT GTXI OSIR QLTI NPSP ARIA POZN ITMN SGEN

Nov 05, 2011 No Comments by

XenoPort, Inc. (Nasdaq: XNPT) announced it completed enrollment of a Phase 2b trial of XP21279 as a potential treatment of patients with Parkinsons disease and expects top-line results by the end of 2011, in line with previous guidance. It also has a PDUFA date for the sNDA of Horizant in the management of post-herpetic neuralgia […]

Daily News Read more

VVUS PDUFA announced. MELA approval + INHX MDVN IMMU AVNR LGND RGRX

Nov 05, 2011 No Comments by

Inhibitex, Inc. (NASDAQ:INHX) today reported top-line safety and antiviral data from the first cohort of its ongoing clinical trial of INX-189, for HCV. In this study, 200 mg INX-189, dosed once-daily for seven days, continued to demonstrate potent and dose-dependent antiviral activity with a median HCV RNA reduction from baseline of -4.25 log10 IU-mL. Further, […]

Daily News Read more